• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[年龄相关性黄斑变性的疾病成本。关于成本日记编制的系统评价]

[Cost of illness of age-related macular degeneration. Systematic review on the development of a costs diary].

作者信息

Gibbert J, Müller D, Fauser S, Stock S

机构信息

Institut für Gesundheitsökonomie und klinische Epidemiologie (IGKE), Uniklinik Köln, Gleueler Strasse 176-178, Köln, Germany.

出版信息

Ophthalmologe. 2013 Jun;110(6):528-36. doi: 10.1007/s00347-012-2750-5.

DOI:10.1007/s00347-012-2750-5
PMID:23297119
Abstract

Due to demographic changes in the German population a significant rise in incident cases of age-related macular degeneration (AMD) is to be expected in the coming years. Also the corresponding increase in costs of the illness requires appropriate survey instruments to allow accurate estimations of costs. The cost diary for patients with AMD developed in this study is based on a previously established systematic review. The seven studies that were included were evaluated regarding their quality in order to then extract the listed cost items. The result is a prospective survey instrument with six different cost sectors of AMD.

摘要

由于德国人口的人口结构变化,预计未来几年年龄相关性黄斑变性(AMD)的发病病例将显著增加。此外,该疾病相应的成本增加需要合适的调查工具来准确估算成本。本研究中开发的AMD患者成本日记基于先前进行的系统评价。对纳入的七项研究进行了质量评估,以便提取所列成本项目。结果是一种针对AMD的具有六个不同成本类别的前瞻性调查工具。

相似文献

1
[Cost of illness of age-related macular degeneration. Systematic review on the development of a costs diary].[年龄相关性黄斑变性的疾病成本。关于成本日记编制的系统评价]
Ophthalmologe. 2013 Jun;110(6):528-36. doi: 10.1007/s00347-012-2750-5.
2
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.抗氧化维生素和矿物质补充剂可减缓与年龄相关的黄斑变性的进展。
Cochrane Database Syst Rev. 2023 Sep 13;9(9):CD000254. doi: 10.1002/14651858.CD000254.pub5.
3
Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.抗血管内皮生长因子生物类似药治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2024 Jun 3;6(6):CD015804. doi: 10.1002/14651858.CD015804.pub2.
4
Blue-light filtering intraocular lenses (IOLs) for protecting macular health.用于保护黄斑健康的蓝光滤过型人工晶状体
Cochrane Database Syst Rev. 2018 May 22;5(5):CD011977. doi: 10.1002/14651858.CD011977.pub2.
5
Artificial intelligence for diagnosing exudative age-related macular degeneration.人工智能在渗出性年龄相关性黄斑变性诊断中的应用。
Cochrane Database Syst Rev. 2024 Oct 17;10(10):CD015522. doi: 10.1002/14651858.CD015522.pub2.
6
Surgery for cataracts in people with age-related macular degeneration.年龄相关性黄斑变性患者的白内障手术
Cochrane Database Syst Rev. 2017 Feb 16;2(2):CD006757. doi: 10.1002/14651858.CD006757.pub4.
7
Relative cost of a line of vision in age-related macular degeneration.年龄相关性黄斑变性中一条视力线的相对成本。
Ophthalmology. 2007 May;114(5):847-54. doi: 10.1016/j.ophtha.2006.10.038. Epub 2007 Feb 16.
8
Cost effectiveness of treatments for wet age-related macular degeneration.湿性年龄相关性黄斑变性治疗的成本效益。
Pharmacoeconomics. 2011 Feb;29(2):107-31. doi: 10.2165/11585520-000000000-00000.
9
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.抗氧化维生素和矿物质补充剂用于延缓年龄相关性黄斑变性的进展。
Cochrane Database Syst Rev. 2017 Jul 31;7(7):CD000254. doi: 10.1002/14651858.CD000254.pub4.
10
Direct and indirect healthcare costs of ocular diseases in Italy: a literature review on glaucoma, diabetic retinopathy, and macular degeneration.意大利眼部疾病的直接和间接医疗成本:关于青光眼、糖尿病性视网膜病变和黄斑变性的文献综述
Ann Ig. 2025 Jul-Aug;37(4):532-555. doi: 10.7416/ai.2025.2676. Epub 2025 Jan 15.

引用本文的文献

1
Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.从社会角度看德国失明和视力损害的经济负担:疾病成本研究。
Eur J Health Econ. 2020 Feb;21(1):115-127. doi: 10.1007/s10198-019-01115-5. Epub 2019 Sep 6.
2
[Macroeconomic costs of eye diseases].[眼科疾病的宏观经济成本]
Ophthalmologe. 2014 May;111(5):420-7. doi: 10.1007/s00347-013-2921-z.
3
[Outcomes and health services research in ophthalmology].[眼科的结局与卫生服务研究]

本文引用的文献

1
Rasch analysis reveals problems with multiplicative scoring in the macular disease quality of life questionnaire.Rasch 分析显示黄斑疾病生活质量问卷的乘法评分存在问题。
Ophthalmology. 2012 Nov;119(11):2351-7. doi: 10.1016/j.ophtha.2012.05.031. Epub 2012 Sep 8.
2
The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration.由新生血管性年龄相关性黄斑变性导致的视力损害的直接、间接和无形成本。
Eur J Health Econ. 2010 Dec;11(6):525-31. doi: 10.1007/s10198-009-0207-9. Epub 2009 Nov 21.
3
Estimating 'costs' for cost-effectiveness analysis.
Ophthalmologe. 2014 May;111(5):414-9. doi: 10.1007/s00347-013-2920-0.
估算成本效益分析中的“成本”。
Pharmacoeconomics. 2008;26(9):745-51. doi: 10.2165/00019053-200826090-00005.
4
[Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].[德国的新生血管性年龄相关性黄斑变性。对生活质量的影响及经济负担]
Ophthalmologe. 2009 Mar;106(3):242-51. doi: 10.1007/s00347-008-1797-9.
5
Burden of illness of bilateral neovascular age-related macular degeneration in Spain.西班牙双侧新生血管性年龄相关性黄斑变性的疾病负担
Curr Med Res Opin. 2008 Jul;24(7):2103-11. doi: 10.1185/03007990802214300. Epub 2008 Jun 10.
6
Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.法国、德国和意大利湿性年龄相关性黄斑变性患者的视力与医疗及非医疗费用之间的关联
Drugs Aging. 2008;25(3):255-68. doi: 10.2165/00002512-200825030-00007.
7
Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost.美国疾病成本研究:对直接成本所用方法的系统评价
Value Health. 2008 Jan-Feb;11(1):13-21. doi: 10.1111/j.1524-4733.2007.00210.x.
8
Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.双侧新生血管性年龄相关性黄斑变性的经济负担:多国观察性研究。
Pharmacoeconomics. 2008;26(1):57-73. doi: 10.2165/00019053-200826010-00006.
9
Burden of illness of neovascular age-related macular degeneration in Canada.加拿大新生血管性年龄相关性黄斑变性的疾病负担。
Can J Ophthalmol. 2007 Dec;42(6):836-43. doi: 10.3129/i07-153.
10
Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.新生血管性年龄相关性黄斑变性患者的疾病负担、视力损害及健康资源利用情况:一项五国横断面研究英国队列的结果
Br J Ophthalmol. 2007 Oct;91(10):1303-7. doi: 10.1136/bjo.2007.116939. Epub 2007 May 15.